Early Results Of a Phase II Study Of Lenalidomide and Rituximab As Frontline Treatment Of Patients With Chronic Lymphocytic Leukemia
Strati P, Keating M, Hinojosa C et al.
Key Points:
Evaluation of efficacy and tolerability of lenalidomide and rituximab as front-line for CLL.
24 of total 25 pts are alive, 1 pt died of metastatic pancreatic cancer. At 9-mont median follow-up, median PFS and median OS not reached.
Implications:
- Combination of lenalidomide and rituximab as front-line treatment of CLL tolerated and responses seen in 85% of enrollees.
View the original abstract on the ASH website.
